ClinicalTrials.Veeva

Menu

Trial to Examine the Effect of Natural Anti- Obesity Agent (Phaseolus Vulgaris) Among Women of Lahore (PVE-AO)

H

Hafiza Aisha Sadiqa

Status

Completed

Conditions

Overweight and Obesity

Treatments

Dietary Supplement: Placebo
Dietary Supplement: Phaseolus Vulgaris

Study type

Interventional

Funder types

Other

Identifiers

NCT05451927
RCT012022

Details and patient eligibility

About

This double-blind randomized placebo-controlled trial will test the hypothesis that administration of Phaseolus Vulgaris supplementation to women in Lahore, Pakistan, who are overweight will induce the weight loss (Primary outcome) and changes in body composition (Waist circumference) secondary outcome.

Enrollment

72 patients

Sex

Female

Ages

18 to 45 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • BMI ranges from 25-40
  • Consistently stable body weight for at least 6 months
  • Good general health
  • No ongoing drug treatment for weight reduction
  • Commitment to avoid any changes in lifestyle throughout the test period
  • Age between 18-45 years
  • Women resident of Lahore

Exclusion criteria

  • Pregnant or breast-feeding females
  • People with Type 2 diabetes
  • People with any other chronic diseases
  • Weight reduction treatment during the 6 months prior to the study

Trial design

Primary purpose

Supportive Care

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

72 participants in 2 patient groups, including a placebo group

Phaseolus Vulgaris
Experimental group
Description:
Three oral doses of 1000 mg Phaseolus Vulgaris daily for 3 months
Treatment:
Dietary Supplement: Phaseolus Vulgaris
Placebo
Placebo Comparator group
Description:
Three oral doses of Placebo daily for 3 months
Treatment:
Dietary Supplement: Placebo

Trial contacts and locations

2

Loading...

Central trial contact

Aisha Sadiqa, M.Phil

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems